Odyssey Medical Technologies

After a fervent US expansion capped by the surprise $150 million licensing of Indevus' OAB treatment Sanctura, proprietary ambitions at the Croatian generics play Pliva may be stalling. Sanctura sales

If the nominal theme of Windhover's 2004 Pharmaceutical Strategic Alliances conference was "transitions", the full subtext was "transitions to sustainability." Sustainability would hardly seem to be

Indevus Pharmaceuticals Inc. 's recent announcement of a US marketing partner for the overactive bladder drug trospium ( Sanctura ) surprised many biotechnology commentators. [See Deal] They were

Buying Sobel Holdings makes Croatia's Pliva one of the first eastern European companies to buy into the US market. It's doing so cleverly, leveraging future revenues from its biggest product, azithrom